ENDVOTCElectromedical & Electrotherapeutic ApparatusFiscal year ends December 31
ENDONOVO THERAPEUTICS, INC.
Financials through Q3 FY2023, quarter ended Sep 30, 2023Last filing: 10-Q/A on Dec 29, 2023
$0.00+0.00 (0.00%)
Close on Oct 19, 2026
- Market cap
- $135.08K
- P/E (TTM)
- –
- Dividend yield
- –
Share price
$0.0000 (0.00%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.
ENDONOVO THERAPEUTICS, INC. grew revenue 1699.9% to $255.72K over the twelve months to Sep 30, 2023.
Revenue
$255.72K
+1699.9% vs. a year earlier
Operating income
-$2.62M
TTM Q3 2023
EPS, diluted
-$0.08
TTM Q3 2023
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Sep 30, 2023
Valuation
- Market cap
- $135.08K
- P/E ratio
- –
- Price to sales
- 0.53
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Revenue
- $255.72K
- Net income
- -$4.40M
- EPS, diluted
- -$0.08
- Book value per share
- -$0.02
- Diluted shares
- 1.35B
Fourteen years at a glance
Fiscal years 2009 to 2022 and trailing twelve months, USD
Revenue
$255.72K+1699.9% YoY
Gross profit
$246.03K+110229.1% YoY
Operating income
-$2.62M
Net income
-$4.40M
EPS, diluted
-$0.08
Free cash flow
–
Reported periodTrailing twelve months